london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

New indications for aflibercept in patients with neovascularisation

Session Details

Session Title: Quick Fire Free Paper 1

Session Date/Time: Thursday 11/09/2014 | 08:00-10:00

Paper Time: 08:10

Venue: Boulevard D

First Author: : A.Korol UKRAINE

Co Author(s): :    O. Zadorozhnyy   T. Kustryn   I. Nasinnyk        

Abstract Details

Purpose:

to explore the possibility of application aflibercept for treatment of neovascularisation associated with pathologic myopia, central chorioretinitis, angiod streaks, diabetic proliferative rethinopathy.

Setting:

SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine» (Odesa, Ukraine)

Methods:

15 patients (15 eyes) with CNV associated with pathologic myopia, 4 patients (5 eyes) with CNV associated with central chorioretinitis, 3 patients (3 eyes) with CNV associated with angiod streaks and 25 patients (25 eyes) with proliferative diabetic retinopathy were observed. Patients with CNV underwent visometry, optical coherence tomography (OCT). Examinations were carried out before treatment and 1, 2, 3, 4 months of follow up. Patients with CNV received intravitreal injections of 2.0 mg (0.05 mL) aflibercept administered every 4 weeks for the first 3 months. In patients with proliferative diabetic retinopathy aflibercept used as preoperative preparation for vitrectomy – single injection of 2.0 mg (4 days before vitrectomy).

Results:

in patients with pathologic myopia mean baseline BCVA was 0.2 (range from 0.06 to 0.5). At the 4th month it was 0.25 (range from 0.06 to 0.6). Mean retinal thickness in fovea showed a reduction from 298 microns (range from 235 to 483 microns) to 245 microns (range from 175 to 297 microns). In patients with central chorioretinitis mean baseline BCVA was 0.36 (range from 0.1 to 0.6). At the 4th month it was 0.4 (range from 0.2 to 0.65). Mean retinal thickness in fovea showed a reduction from 320 microns (range from 265 to 528 microns) to 278 microns (range from 228 to 362 microns). In patients with angiod streaks mean BCVA improved from 0.33 (range from 0.1 to 0.6) to 0.6 (range from 0.2 to 0.9). Mean retinal thickness in fovea was 387 microns (range from 274 to 548 microns). At the 4th month it was 280 microns (range from 235 to 417 microns). In patients with proliferative diabetic retinopathy vitrectomy passed without intraoperative bleeding within removing epiretinal membranes and without postoperatively hemorrhage was absent. The time mean of surgery decreased on 10 minutes.

Conclusions:

aflibercept may be used for the treatment of CNV associated with pathologic myopia, central chorioretinitis amd angiod streaks. Aflibercept also may be effective for prevention of intra- and postoperative bleeding in patient with proliferative diabetic retinopathy.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy